FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:987-994 September 30, 1993 Number 14 Next

	Full Text Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Although many patients with intermediate-grade or high-grade (aggressive) non-Hodgkin's lymphoma are cured by combination chemotherapy, the remainder are not cured and ultimately die of their disease. The Ann Arbor classification, used to determine the stage of this disease, does not consistently distinguish between patients with different long-term prognoses. This project was undertaken to develop a model for predicting outcome in patients with aggressive non-Hodgkin's lymphoma on the basis of the patients' clinical characteristics before treatment.

Methods Adults with aggressive non-Hodgkin's lymphoma from 16 institutions and cooperative groups in the United States, Europe, and Canada who were treated between 1982 and 1987 with combination-chemotherapy regimens containing doxorubicin were evaluated for clinical features predictive of overall survival and relapse-free survival. Features that remained independently significant in step-down regression analyses of survival were incorporated into models that identified groups of patients of all ages and groups of patients no more than 60 years old with different risks of death.

Results In 2031 patients of all ages, our model, based on age, tumor stage, serum lactate dehydrogenase concentration, performance status, and number of extranodal disease sites, identified four risk groups with predicted five-year survival rates of 73 percent, 51 percent, 43 percent, and 26 percent. In 1274 patients 60 or younger, an age-adjusted model based on tumor stage, lactate dehydrogenase level, and performance status identified four risk groups with predicted five-year survival rates of 83 percent, 69 percent, 46 percent, and 32 percent. In both models, the increased risk of death was due to both a lower rate of complete responses and a higher rate of relapse from complete response. These two indexes, called the international index and the age-adjusted international index, were significantly more accurate than the Ann Arbor classification in predicting long-term survival.

Conclusions The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.

Source Information

The following persons are members of the International Non-Hodgkin's Lymphoma Prognostic Factors Project: M.A. Shipp (Dana-Farber Cancer Institute and Harvard Medical School, Boston) and D.P. Harrington (Dana-Farber Cancer Institute and Harvard Medical School, Boston; Eastern Cooperative Oncology Group, Denver), chairpersons; J.R. Anderson (Nebraska Lymphoma Study Group, Omaha; Cancer and Leukemia Group B, Lebanon, N.H.); J.O. Armitage (Nebraska Lymphoma Study Group, Omaha); G. Bonadonna (Istituto Nazionale Tumori, Milan, Italy); G. Brittinger (Bundesministerium fur Forschung und Technologie Study, Essen, Germany); F. Cabanillas (M.D. Anderson Cancer Center, Houston); G.P. Canellos (Dana-Farber Cancer Institute and Harvard Medical School, Boston); B. Coiffier (Groupe d'Etude des Lymphomes de l'Adulte, Paris); J.M. Connors (British Columbia Cancer Agency, Vancouver); R.A. Cowan and D. Crowther (Manchester Lymphoma Group, Manchester, United Kingdom); S. Dahlberg (Southwest Oncology Group, San Antonio, Tex.); M. Engelhard (Bundesministerium fur Forschung und Technologie Study, Essen, Germany); R.I. Fisher (Southwest Oncology Group, San Antonio, Tex.); C. Gisselbrecht (Groupe d'Etude des Lymphomes de l'Adulte, Paris); S.J. Horning (Stanford University, Stanford, Calif.); E. Lepage (Groupe d'Etude des Lymphomes de l'Adulte, Paris); T.A. Lister (St. Bartholomew's Hospital, London); J.H. Meerwaldt (Lymphoma Cooperative Group, European Organisation for Research on Treatment of Cancer, Brussels, Belgium); E. Montserrat (Hospital Clinic i Provincial de Barcelona, Barcelona, Spain); N.I. Nissen (Finsen Institute, Copenhagen, Denmark); M.M. Oken (Eastern Cooperative Oncology Group, Denver); B.A. Peterson (Cancer and Leukemia Group B, Lebanon, N.H.); C. Tondini (Istituto Nazionale Tumori, Milan, Italy); W.A. Velasquez (M.D. Anderson Cancer Center, Houston); and B.Y. Yeap (Dana-Farber Cancer Institute and Harvard Medical School, Boston; Eastern Cooperative Oncology Group, Denver).

Address reprint requests to Dr. Margaret A. Shipp at the Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115.

Full Text of this Article

Related Letters:

A Predictive Model for Non-Hodgkin's Lymphoma
Atkins C. D., Moore G. E., Shipp M. A., Harrington D. P.
Extract | Full Text  
N Engl J Med 1994; 330:574-575, Feb 24, 1994. Correspondence

Bone Marrow Transplantation versus Chemotherapy in Non-Hodgkin's Lymphoma
Seymour J. F., Flecknoe-Brown S., Mross K., Burke H. B., Nimer S. D., Zelenetz A., Portlock C., Finckh W., Fielding A. K., Pearce R. M., Goldstone A. H., Selwyn M. R., Verdonck L. F., van Putten W. L.J., Hagenbeek A., Walker A. M.
Extract | Full Text  
N Engl J Med 1995; 333:727-730, Sep 14, 1995. Correspondence

This article has been cited by other articles:

• Chau, I., Ashley, S., Cunningham, D. (2009). Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study. JCO 27: e3-e4 [Full Text]  
• Ray-Coquard, I., Cropet, C., Van Glabbeke, M., Sebban, C., Le Cesne, A., Judson, I., Tredan, O., Verweij, J., Biron, P., Labidi, I., Guastalla, J.-P., Bachelot, T., Perol, D., Chabaud, S., Hogendoorn, P. C.W., Cassier, P., Dufresne, A., Blay, J.-Y., on behalf of the European Organization for Researc, (2009). Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas. Cancer Res. 69: 5383-5391 [Abstract] [Full Text]  
• Martinelli, G., Ryan, G., Seymour, J. F., Nassi, L., Steffanoni, S., Alietti, A., Calabrese, L., Pruneri, G., Santoro, L., Kuper-Hommel, M., Tsang, R., Zinzani, P. L., Taghian, A., Zucca, E., Cavalli, F. (2009). Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. Ann Oncol 0: mdp238v1-mdp238 [Abstract] [Full Text]  
• Yang, Z.-Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E., Ansell, S. M. (2009). Malignant B Cells Skew the Balance of Regulatory T Cells and TH17 Cells in B-Cell Non-Hodgkin's Lymphoma. Cancer Res. 69: 5522-5530 [Abstract] [Full Text]  
• Tomita, N., Tokunaka, M., Nakamura, N., Takeuchi, K., Koike, J., Motomura, S., Miyamoto, K., Kikuchi, A., Hyo, R., Yakushijin, Y., Masaki, Y., Fujii, S., Hayashi, T., Ishigatsubo, Y., Miura, I. (2009). Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. haematol 94: 935-943 [Abstract] [Full Text]  
• Hodby, K, Fields, P A (2009). Management of lymphoma in pregnancy. Obstet Med 2: 46-51 [Abstract] [Full Text]  
• Hohaus, S., Giachelia, M., Massini, G., Mansueto, G., Vannata, B., Bozzoli, V., Criscuolo, M., D'Alo, F., Martini, M., Larocca, L. M., Voso, M. T., Leone, G. (2009). Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol 0: mdp006v1-mdp006 [Abstract] [Full Text]  
• NISHIMORI, H., FUJII, N., MAEDA, Y., MATSUOKA, K.-I., TAKENAKA, K., SHINAGAWA, K., IKEDA, K., MATSUO, K., HARADA, M., TANIMOTO, M. (2009). Efficacy and Feasibility of IDEA Therapy for Refractory or Relapsed Non-Hodgkin's Lymphoma. Anticancer Res 29: 1749-1754 [Abstract] [Full Text]  
• Hutchings, M., Barrington, S. F. (2009). PET/CT for Therapy Response Assessment in Lymphoma. JNM 50: 21S-30S [Abstract] [Full Text]  
• Tilly, H., Dreyling, M., On behalf of the ESMO Guidelines Working Group, (2009). Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv110-iv112 [Full Text]  
• Morel, P., Duhamel, A., Gobbi, P., Dimopoulos, M. A., Dhodapkar, M. V., McCoy, J., Crowley, J., Ocio, E. M., Garcia-Sanz, R., Treon, S. P., Leblond, V., Kyle, R. A., Barlogie, B., Merlini, G. (2009). International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113: 4163-4170 [Abstract] [Full Text]  
• Au, W.-y., Weisenburger, D. D., Intragumtornchai, T., Nakamura, S., Kim, W.-S., Sng, I., Vose, J., Armitage, J. O., Liang, R., for the International Peripheral T-Cell Lymphoma P, (2009). Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113: 3931-3937 [Abstract] [Full Text]  
• Li, Y.-X., Liu, Q.-F., Fang, H., Qi, S.-N., Wang, H., Wang, W.-H., Song, Y.-W., Lu, J., Jin, J., Wang, S.-L., Liu, Y.-P., Lu, N., Liu, X.-F., Yu, Z.-H. (2009). Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma. Clin. Cancer Res. 15: 2905-2912 [Abstract] [Full Text]  
• Terasawa, T., Lau, J., Bardet, S., Couturier, O., Hotta, T., Hutchings, M., Nihashi, T., Nagai, H. (2009). Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review. JCO 27: 1906-1914 [Abstract] [Full Text]  
• Luigi Zinzani, P., Stefoni, V., Tani, M., Fanti, S., Musuraca, G., Castellucci, P., Marchi, E., Fina, M., Ambrosini, V., Pellegrini, C., Alinari, L., Derenzini, E., Montini, G., Broccoli, A., Bacci, F., Pileri, S., Baccarani, M. (2009). Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma. JCO 27: 1781-1787 [Abstract] [Full Text]  
• Suzumiya, J., Ohshima, K., Tamura, K., Karube, K., Uike, N., Tobinai, K., Gascoyne, R. D., Vose, J. M., Armitage, J. O., Weisenburger, D. D., for the International Peripheral T-cell Lymphoma P, (2009). The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project. Ann Oncol 20: 715-721 [Abstract] [Full Text]  
• Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R. R., Ruan, J., Elstrom, R., Niesvizky, R., Ely, S., DiLiberto, M., Melnick, A., Knowles, D. M., Chen-Kiang, S., Coleman, M., Leonard, J. P. (2009). Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma. JCO 27: 1209-1213 [Abstract] [Full Text]  
• Friedberg, J. W., Taylor, M. D., Cerhan, J. R., Flowers, C. R., Dillon, H., Farber, C. M., Rogers, E. S., Hainsworth, J. D., Wong, E. K., Vose, J. M., Zelenetz, A. D., Link, B. K. (2009). Follicular Lymphoma in the United States: First Report of the National LymphoCare Study. JCO 27: 1202-1208 [Abstract] [Full Text]  
• McLaughlin, P. (2009). A Look in the Mirror. JCO 27: 1158-1159 [Full Text]  
• Ennishi, D., Yokoyama, M., Terui, Y., Asai, H., Sakajiri, S., Mishima, Y., Takahashi, S., Komatsu, H., Ikeda, K., Takeuchi, K., Tanimoto, M., Hatake, K. (2009). Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 20: 526-533 [Abstract] [Full Text]  
• Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Reiser, M., Forstpointner, R., Metzner, B., Peter, N., Wormann, B., Trumper, L., Pfreundschuh, M., Einsele, H., Hiddemann, W., Unterhalt, M., Dreyling, M. (2009). Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma. JCO 27: 511-518 [Abstract] [Full Text]  
• Sjo, L. D., Heegaard, S., Prause, J. U., Petersen, B. L., Pedersen, S., Ralfkiaer, E. (2009). Extranodal Marginal Zone Lymphoma in the Ocular Region: Clinical, Immunophenotypical, and Cytogenetical Characteristics. IOVS 50: 516-522 [Abstract] [Full Text]  
• Lee, R. V., Green, C. A., Negrea, O. G., Dodson, S., Farrell, S. K., Hewitt, J. E., Jago, T., Ramsey, C. E., Cato, T., Crawford, E., Henley, D. C., Phelan, M. C., Potter, N. T. (2009). B-Cell Lymphoma With Intermediate- to High-Grade Features and Different Immunophenotypic Profiles Involving Separate Anatomic Sites With a Good Response to R-CHOP. Lab Med 40: 79-86 [Abstract] [Full Text]  
• Buchner, T., Berdel, W. E., Haferlach, C., Haferlach, T., Schnittger, S., Muller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., Gruneisen, A., Kern, W., Reichle, A., Maschmeyer, G., Aul, C., Lengfelder, E., Sauerland, M.-C., Heinecke, A., Wormann, B., Hiddemann, W. (2009). Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group. JCO 27: 61-69 [Abstract] [Full Text]  
• Bernstein, S. H., Unger, J. M., LeBlanc, M., Friedberg, J., Miller, T. P., Fisher, R. I. (2009). Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516--The Southwest Oncology Group. JCO 27: 114-119 [Abstract] [Full Text]  
• Hallack Neto, A E, Siqueira, S A C, Dulley, F L, Ruiz, M A, Chamone, D A F, Pereira, J (2009). p63 Protein expression in high risk diffuse large B-cell lymphoma. J. Clin. Pathol. 62: 77-79 [Abstract] [Full Text]  
• Balfe, M. (2009). The Body Projects of University Students with Type 1 Diabetes. Qual Health Res 19: 128-139 [Abstract]  
• Vose, J. M. (2009). The International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: What Have We Learned?. Am Soc Clin Oncol Ed Book 2009: 490-493 [Abstract] [Full Text]  
• Sandlund, J. T. (2009). Clinical Features and Treatment Approaches for the Uncommon Non-Hodgkin Lymphoma Subtypes in Children. Am Soc Clin Oncol Ed Book 2009: 598-603 [Abstract] [Full Text]  
• Salles, G., Mounier, N., de Guibert, S., Morschhauser, F., Doyen, C., Rossi, J.-F., Haioun, C., Brice, P., Mahe, B., Bouabdallah, R., Audhuy, B., Ferme, C., Dartigeas, C., Feugier, P., Sebban, C., Xerri, L., Foussard, C. (2008). Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112: 4824-4831 [Abstract] [Full Text]  
• Shetty, S., Holt, A.P., Syn, W.-K., Fox, C.P., Gunson, B., Neil, D., Haydon, G. (2008). Haematological malignancies presenting with acute liver injury: a single-centre experience. QJM 101: 949-953 [Abstract] [Full Text]  
• Jaffe, E. S., Harris, N. L., Stein, H., Isaacson, P. G. (2008). Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 112: 4384-4399 [Abstract] [Full Text]  
• Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E.B., Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Muller-Hermelink, H.-K., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C., Staudt, L.M., the Lymphoma/Leukemia Molecular Profiling Project, (2008). Stromal Gene Signatures in Large-B-Cell Lymphomas. NEJM 359: 2313-2323 [Abstract] [Full Text]  
• Devizzi, L., Guidetti, A., Tarella, C., Magni, M., Matteucci, P., Seregni, E., Chiesa, C., Bombardieri, E., Di Nicola, M., Carlo-Stella, C., Gianni, A. M. (2008). High-Dose Yttrium-90-Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation. JCO 26: 5175-5182 [Abstract] [Full Text]  
• Khanna, D., Furst, D. E., Clements, P. J., Tashkin, D. P., Eckman, M. H. (2008). Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis. Med Decis Making 28: 926-937 [Abstract]  
• Ennishi, D., Takeuchi, K., Yokoyama, M., Asai, H., Mishima, Y., Terui, Y., Takahashi, S., Komatsu, H., Ikeda, K., Yamaguchi, M., Suzuki, R., Tanimoto, M., Hatake, K. (2008). CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 19: 1921-1926 [Abstract] [Full Text]  
• Suh, C., Kang, Y.-K., Roh, J.-L., Kim, M. R., Kim, J. S., Huh, J., Lee, J. H., Jang, Y. J., Lee, B.-J. (2008). Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck. JNM 49: 1783-1789 [Abstract] [Full Text]  
• Rimsza, L. M., LeBlanc, M. L., Unger, J. M., Miller, T. P., Grogan, T. M., Persky, D. O., Martel, R. R., Sabalos, C. M., Seligmann, B., Braziel, R. M., Campo, E., Rosenwald, A., Connors, J. M., Sehn, L. H., Johnson, N., Gascoyne, R. D. (2008). Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 112: 3425-3433 [Abstract] [Full Text]  
• Li, Y.-X., Fang, H., Liu, Q.-F., Lu, J., Qi, S.-N., Wang, H., Jin, J., Wang, W.-H., Liu, Y.-P., Song, Y.-W., Wang, S.-L., Liu, X.-F., Feng, X.-L., Yu, Z.-H. (2008). Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood 112: 3057-3064 [Abstract] [Full Text]  
• Talaulikar, D., Dahlstrom, J. E., Shadbolt, B., Broomfield, A., McDonald, A. (2008). Role of Immunohistochemistry in Staging Diffuse Large B-cell Lymphoma (DLBCL). J. Histochem. Cytochem. 56: 893-900 [Abstract] [Full Text]  
• Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J. V., Dmoszynska, A., Raposo, J. C., Offner, F. C., Gomez-Codina, J., Belch, A., Cunningham, D., Wassner-Fritsch, E., Stein, G. (2008). Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma. JCO 26: 4579-4586 [Abstract] [Full Text]  
• Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., Eriksson, M., Nordstrom, M., Kimby, E., Boesen, A. M., Kuittinen, O., Lauritzsen, G. F., Nilsson-Ehle, H., Ralfkiaer, E., Akerman, M., Ehinger, M., Sundstrom, C., Langholm, R., Delabie, J., Karjalainen-Lindsberg, M.-L., Brown, P., Elonen, E., for the Nordic Lymphoma Group, (2008). Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112: 2687-2693 [Abstract] [Full Text]  
• Habermann, T. M., Wang, S. S., Maurer, M. J., Morton, L. M., Lynch, C. F., Ansell, S. M., Hartge, P., Severson, R. K., Rothman, N., Davis, S., Geyer, S. M., Cozen, W., Chanock, S. J., Cerhan, J. R. (2008). Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 112: 2694-2702 [Abstract] [Full Text]  
• Mead, G. M., Barrans, S. L., Qian, W., Walewski, J., Radford, J. A., Wolf, M., Clawson, S. M., Stenning, S. P., Yule, C. L., Jack, A. S., on behalf of the UK National Cancer Research Insti, (2008). A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 112: 2248-2260 [Abstract] [Full Text]  
• International T-Cell Lymphoma Project, (2008). International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes. JCO 26: 4124-4130 [Abstract] [Full Text]  
• Sacchi, S., Marcheselli, L., Bari, A., Marcheselli, R., Pozzi, S., Gobbi, P. G., Angrilli, F., Brugiatelli, M., Musto, P., Federico, M. (2008). Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. haematol 93: 1335-1342 [Abstract] [Full Text]  
• Kim, T. M., Lee, S. -Y., Jeon, Y. K., Ryoo, B. -Y., Cho, G. J., Hong, Y. S., Kim, H. J., Kim, S.-Y., Kim, C. S., Kim, S., Kim, J. S., Sohn, S. K., Song, H. H., Lee, J. L., Kang, Y. K., Yim, C. Y., Lee, W. S., Yuh, Y. J., Kim, C. W., Heo, D. S., for the Lymphoma Subcommittee of the Korean Cancer, (2008). Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 19: 1477-1484 [Abstract] [Full Text]  
• Yamaguchi, M., Nakamura, N., Suzuki, R., Kagami, Y., Okamoto, M., Ichinohasama, R., Yoshino, T., Suzumiya, J., Murase, T., Miura, I., Ohshima, K., Nishikori, M., Tamaru, J.-i., Taniwaki, M., Hirano, M., Morishima, Y., Ueda, R., Shiku, H., Nakamura, S. (2008). De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. haematol 93: 1195-1202 [Abstract] [Full Text]  
• Tarella, C., Zanni, M., Magni, M., Benedetti, F., Patti, C., Barbui, T., Pileri, A., Boccadoro, M., Ciceri, F., Gallamini, A., Cortelazzo, S., Majolino, I., Mirto, S., Corradini, P., Passera, R., Pizzolo, G., Gianni, A. M., Rambaldi, A. (2008). Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi Survey. JCO 26: 3166-3175 [Abstract] [Full Text]  
• Shimada, K., Matsue, K., Yamamoto, K., Murase, T., Ichikawa, N., Okamoto, M., Niitsu, N., Kosugi, H., Tsukamoto, N., Miwa, H., Asaoku, H., Kikuchi, A., Matsumoto, M., Saburi, Y., Masaki, Y., Yamaguchi, M., Nakamura, S., Naoe, T., Kinoshita, T. (2008). Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan. JCO 26: 3189-3195 [Abstract] [Full Text]  
• Savage, K. J., Harris, N. L., Vose, J. M., Ullrich, F., Jaffe, E. S., Connors, J. M., Rimsza, L., Pileri, S. A., Chhanabhai, M., Gascoyne, R. D., Armitage, J. O., Weisenburger, D. D., for the International Peripheral T-Cell Lymphoma P, (2008). ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111: 5496-5504 [Abstract] [Full Text]  
• Khouri, I. F., McLaughlin, P., Saliba, R. M., Hosing, C., Korbling, M., Lee, M. S., Medeiros, L. J., Fayad, L., Samaniego, F., Alousi, A., Anderlini, P., Couriel, D., de Lima, M., Giralt, S., Neelapu, S. S., Ueno, N. T., Samuels, B. I., Hagemeister, F., Kwak, L. W., Champlin, R. E. (2008). Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111: 5530-5536 [Abstract] [Full Text]  
• Malumbres, R., Chen, J., Tibshirani, R., Johnson, N. A., Sehn, L. H., Natkunam, Y., Briones, J., Advani, R., Connors, J. M., Byrne, G. E., Levy, R., Gascoyne, R. D., Lossos, I. S. (2008). Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 111: 5509-5514 [Abstract] [Full Text]  
• Wilson, W. H., Dunleavy, K., Pittaluga, S., Hegde, U., Grant, N., Steinberg, S. M., Raffeld, M., Gutierrez, M., Chabner, B. A., Staudt, L., Jaffe, E. S., Janik, J. E. (2008). Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. JCO 26: 2717-2724 [Abstract] [Full Text]  
• Persky, D. O., Unger, J. M., Spier, C. M., Stea, B., LeBlanc, M., McCarty, M. J., Rimsza, L. M., Fisher, R. I., Miller, T. P. (2008). Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014. JCO 26: 2258-2263 [Abstract] [Full Text]  
• Mercadal, S., Briones, J., Xicoy, B., Pedro, C., Escoda, L., Estany, C., Camos, M., Colomo, L., Espinosa, I., Martinez, S., Ribera, J.M., Martino, R., Gutierrez-Garcia, G., Montserrat, E., Lopez-Guillermo, A., On behalf of the Grup per l'Estudi dels Limfomes d, (2008). Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19: 958-963 [Abstract] [Full Text]  
• Dierlamm, J., Murga Penas, E. M., Bentink, S., Wessendorf, S., Berger, H., Hummel, M., Klapper, W., Lenze, D., Rosenwald, A., Haralambieva, E., Ott, G., Cogliatti, S. B., Moller, P., Schwaenen, C., Stein, H., Loffler, M., Spang, R., Trumper, L., Siebert, R., for the Deutsche Krebshilfe Network Project "Molec, (2008). Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma. haematol 93: 688-696 [Abstract] [Full Text]  
• Mourad, N., Mounier, N., Briere, J., Raffoux, E., Delmer, A., Feller, A., Meijer, C. J. L. M., Emile, J.-F., Bouabdallah, R., Bosly, A., Diebold, J., Haioun, C., Coiffier, B., Gisselbrecht, C., Gaulard, P. (2008). Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 111: 4463-4470 [Abstract] [Full Text]  
• Canellos, G. P. (2008). What Constitutes "Improved Prognosis"?. JCO 26: 1913-1914 [Full Text]  
• Ladetto, M., De Marco, F., Benedetti, F., Vitolo, U., Patti, C., Rambaldi, A., Pulsoni, A., Musso, M., Liberati, A. M., Olivieri, A., Gallamini, A., Pogliani, E., Scalabrini, D. R., Callea, V., Di Raimondo, F., Pavone, V., Tucci, A., Cortelazzo, S., Levis, A., Boccadoro, M., Majolino, I., Pileri, A., Gianni, A. M., Passera, R., Corradini, P., Tarella, C., for Gruppo Italiano Trapianto di Midollo Osseo (GI, (2008). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111: 4004-4013 [Abstract] [Full Text]  
• Ziepert, M., Schmits, R., Trumper, L., Pfreundschuh, M., Loeffler, M., On behalf of the German High-Grade Non-Hodgkin's L, (2008). Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma. Ann Oncol 19: 752-762 [Abstract] [Full Text]  
• Thieblemont, C., Grossoeuvre, A., Houot, R., Broussais-Guillaumont, F., Salles, G., Traulle, C., Espinouse, D., Coiffier, B. (2008). Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19: 774-779 [Abstract] [Full Text]  
• Zinzani, P. L., Tani, M., Fanti, S., Stefoni, V., Musuraca, G., Castellucci, P., Marchi, E., Farsad, M., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Bacci, F., Pileri, S., Baccarani, M. (2008). A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 19: 769-773 [Abstract] [Full Text]  
• Pfreundschuh, M., Zwick, C., Zeynalova, S., Duhrsen, U., Pfluger, K.-H., Vrieling, T., Mesters, R., Mergenthaler, H.-G., Einsele, H., Bentz, M., Lengfelder, E., Trumper, L., Rube, C., Schmitz, N., Loeffler, M., On behalf of the German High-Grade Non-Hodgkin's L, (2008). Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 19: 545-552 [Abstract] [Full Text]  
• Overman, M. J., Feng, L., Pro, B., McLaughlin, P., Hess, M., Samaniego, F., Younes, A., Romaguera, J. E., Hagemeister, F. B., Kwak, L., Cabanillas, F., Rodriguez, M. A., Fayad, L. E. (2008). The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 19: 553-559 [Abstract] [Full Text]  
• Morel, P., Gaulard, P., Gisselbrecht, C., Ferme, C., Salles, G., Tilly, H., Briere, J., Copin, M. C., Lederlin, P., Hermine, O., Theate, I., Haioun, C., Mounier, N. (2008). Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. Ann Oncol 19: 560-565 [Abstract] [Full Text]  
• Trumper, L., Zwick, C., Ziepert, M., Hohloch, K., Schmits, R., Mohren, M., Liersch, R., Bentz, M., Graeven, U., Wruck, U., Hoffmann, M., Metzner, B., Hasenclever, D., Loeffler, M., Pfreundschuh, M., On behalf of the German High-Grade Non-Hodgkin's L, (2008). Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol 19: 538-544 [Abstract] [Full Text]  
• Traverse-Glehen, A., Baseggio, L., Bauchu, E. C., Morel, D., Gazzo, S., Ffrench, M., Verney, A., Rolland, D., Thieblemont, C., Magaud, J.-P., Salles, G., Coiffier, B., Berger, F., Felman, P. (2008). Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?. Blood 111: 2253-2260 [Abstract] [Full Text]  
• Ryan, G., Martinelli, G., Kuper-Hommel, M., Tsang, R., Pruneri, G., Yuen, K., Roos, D., Lennard, A., Devizzi, L., Crabb, S., Hossfeld, D., Pratt, G., Dell'Olio, M., Choo, S. P., Bociek, R. G., Radford, J., Lade, S., Gianni, A. M., Zucca, E., Cavalli, F., Seymour, J. F. (2008). Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 19: 233-241 [Abstract] [Full Text]  
• Le Deley, M.-C., Reiter, A., Williams, D., Delsol, G., Oschlies, I., McCarthy, K., Zimmermann, M., Brugieres, L., on behalf of the European Intergroup for Childhood, (2008). Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood 111: 1560-1566 [Abstract] [Full Text]  
• Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H. C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., Peter, N., Jung, W., Wormann, B., Ludwig, W.-D., Duhrsen, U., Eimermacher, H., Wandt, H., Hasford, J., Hiddemann, W., Unterhalt, M., for the German Low Grade Lymphoma Study Group (GLS, (2008). A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111: 558-565 [Abstract] [Full Text]  
• Sasaki, S., Shikama, N., Koiwai, K., Kadoya, M. (2008). Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment. Jpn J Clin Oncol 38: 43-48 [Abstract] [Full Text]  
• Terasawa, T., Nihashi, T., Hotta, T., Nagai, H. (2008). 18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review. JNM 49: 13-21 [Abstract] [Full Text]  
• Johnson, P. W.M., Davies, A. J. (2008). Primary Mediastinal B-Cell Lymphoma. ASH Education Book 2008: 349-358 [Abstract] [Full Text]  
• Tsukasaki, K., Utsunomiya, A., Fukuda, H., Shibata, T., Fukushima, T., Takatsuka, Y., Ikeda, S., Masuda, M., Nagoshi, H., Ueda, R., Tamura, K., Sano, M., Momita, S., Yamaguchi, K., Kawano, F., Hanada, S., Tobinai, K., Shimoyama, M., Hotta, T., Tomonaga, M. (2007). VCAP-AMP-VECP Compared With Biweekly CHOP for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study JCOG9801. JCO 25: 5458-5464 [Abstract] [Full Text]  
• Oh, D.-E., Kim, Y.-D. (2007). Lymphoproliferative Diseases of the Ocular Adnexa in Korea. Arch Ophthalmol 125: 1668-1673 [Abstract] [Full Text]  
• Lofstrom, B, Backlin, C, Sundstrom, C, Ekbom, A, Lundberg, I E (2007). A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 66: 1627-1632 [Abstract] [Full Text]  
• Seam, P., Juweid, M. E., Cheson, B. D. (2007). The role of FDG-PET scans in patients with lymphoma. Blood 110: 3507-3516 [Abstract] [Full Text]  
• Davies, C.L., Chinn, R., Nelson, M., Rasanesan, M., Gazzard, B., Powles, T., Bower, M., Stebbing, J. (2007). Outcome in AIDS-Related Systemic Non-Hodgkin Lymphoma and Leptomeningeal Disease Is Not Predicted by a CT Brain Scan. Am. J. Neuroradiol. 28: 1988-1990 [Abstract] [Full Text]  
• Federico, M., Guglielmi, C., Luminari, S., Mammi, C., Marcheselli, L., Gianelli, U., Maiorana, A., Merli, F., Bellei, M., Pozzi, S., Stelitano, C., Lazzaro, A., Gobbi, P. G., Baldini, L., Bergantini, S., Fregoni, V., Brugiatelli, M. (2007). Prognostic relevance of serum {beta}2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. haematol 92: 1482-1488 [Abstract] [Full Text]  
• Le Gouill, S., Talmant, P., Touzeau, C., Moreau, A., Garand, R., Juge-Morineau, N., Gaillard, F., Gastinne, T., Milpied, N., Moreau, P., Harousseau, J. L., Avet-Loiseau, H. (2007). The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. haematol 92: 1335-1342 [Abstract] [Full Text]  
• Taskinen, M., Karjalainen-Lindsberg, M.-L., Nyman, H., Eerola, L.-M., Leppa, S. (2007). A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone. Clin. Cancer Res. 13: 5784-5789 [Abstract] [Full Text]  
• Ferreri, A. J. M., Reni, M., Zucca, E., Cavalli, F. (2007). Primary CNS Lymphomas Prognosis. JCO 25: 4322-4324 [Full Text]  
• Oyama, T., Yamamoto, K., Asano, N., Oshiro, A., Suzuki, R., Kagami, Y., Morishima, Y., Takeuchi, K., Izumo, T., Mori, S., Ohshima, K., Suzumiya, J., Nakamura, N., Abe, M., Ichimura, K., Sato, Y., Yoshino, T., Naoe, T., Shimoyama, Y., Kamiya, Y., Kinoshita, T., Nakamura, S. (2007). Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients. Clin. Cancer Res. 13: 5124-5132 [Abstract] [Full Text]